INNOVOTECH INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.12 CAD | -7.69% |
|
-7.69% | +60.00% |
| 25/04 | Innovotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Innovotech Inc. Announces CFO Changes | CI |
| Sales 2022 | 1.13M 823K 68.68M | Sales 2023 | 1.18M 864K 72.14M | Capitalization | 2.92M 2.13M 178M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 0 | Net income 2023 | - 0 0 | EV / Sales 2022 | 4.21 x |
| Net cash position 2022 | 514K 375K 31.34M | Net cash position 2023 | 229K 167K 13.95M | EV / Sales 2023 | 2.27 x |
| P/E ratio 2022 |
-38.5
x | P/E ratio 2023 |
-18.5
x | Employees | 14 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 57.3% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -7.69% | ||
| 1 week | -7.69% | ||
| Current month | +9.09% | ||
| 1 month | +9.09% | ||
| 3 months | +20.00% | ||
| 6 months | +20.00% | ||
| Current year | +60.00% |
1 week
0.12
0.12
1 month
0.110.13
Current year
0.020.13
1 year
0.020.15
3 years
0.020.23
5 years
0.000.30
10 years
0.000.30
| Managers | Title | Age | Since |
|---|---|---|---|
Craig Milne
CEO | Chief Executive Officer | - | 19/19/19 |
| Director of Finance/CFO | - | 30/13/30 | |
James Timourian
CHM | Chairman | - | 22/02/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Karen L. Farkas
BRD | Director/Board Member | - | 15/19/15 |
Alan Savage
BRD | Director/Board Member | - | 02/17/02 |
James Timourian
CHM | Chairman | - | 22/02/22 |
Innovotech Inc. is a Canada-based biotechnology company. The Company is engaged in owning intellectual property, conducting contract research, and owning and providing devices for testing in multiple applications in microbiology. Its contract research services include Antimicrobial Contract Research; Antimicrobial and Anti-Biofilm Agents, including Minimum Inhibitory Concentration (MIC) and Minimum Biofilm; Eradication Concentration (MBEC); Antimicrobial and Anti-Biofilm Materials, including TM100, ISO 22196 and USP 51; Customized Antimicrobial Testing, including BEST Assay Testing and Implanted Medical Device Testing; Bacteriophage Testing; and Analytical Capabilities. It also offers MBEC Assay Kits, Order Biofilm Assays and Coated MBEC Assay Lids. Its biofilm research includes The Science of Biofilms, Biofilm Publications and SEM Library. Its antimicrobial silver products include AgreGuard-1 Silver Antimicrobial for Crop Protection and InnovoSIL Antimicrobial Silver Products.
Calendar
21/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +60.00% | 3.42M | |
| +1.77% | 42.75B | |
| +47.70% | 41.61B | |
| +12.24% | 41.34B | |
| -8.83% | 26.59B | |
| +7.44% | 25.49B | |
| -23.01% | 18.12B | |
| +30.56% | 12.24B | |
| -1.82% | 11.76B | |
| +8.35% | 11B |
- Stock Market
- Equities
- IOT Stock
